{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:51:29Z","timestamp":1790128289389,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s13555-026-01666-5","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T15:48:14Z","timestamp":1771516094000},"page":"1707-1721","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Remibrutinib Showed a Favorable Safety Profile and Sustained Efficacy in Japanese Patients with Chronic Spontaneous Urticaria Over 52\u00a0Weeks"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8651-2493","authenticated-orcid":false,"given":"Koremasa","family":"Hayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Chinuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Yagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Kume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuya","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakiko","family":"Miyazu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Lheritier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Jaskiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Haemmerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Hide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"issue":"3","key":"1666_CR1","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/all.15090","volume":"77","author":"T Zuberbier","year":"2022","unstructured":"Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI\/GA(2)LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734\u201366.","journal-title":"Allergy"},{"issue":"10","key":"1666_CR2","first-page":"1394","volume":"67","author":"M Hide","year":"2018","unstructured":"Hide M. Japanese guidelines for diagnosis and treatment of urticaria 2018. Arerugi. 2018;67(10):1394\u20138.","journal-title":"Arerugi"},{"issue":"2","key":"1666_CR3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/all.14037","volume":"75","author":"J Fricke","year":"2020","unstructured":"Fricke J, Avila G, Keller T, et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy. 2020;75(2):423\u201332.","journal-title":"Allergy"},{"key":"1666_CR4","unstructured":"Patient survey 2023. Ministry of Health, Labor and Welfare. http:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/kanja\/10syoubyo\/index.html (in Japanese). Accessed 5 Aug 2024."},{"issue":"4","key":"1666_CR5","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.3390\/jcm14041162","volume":"14","author":"M Hide","year":"2025","unstructured":"Hide M, Uda A, Maki F, et al. Prevalence and burden of chronic spontaneous urticaria in Japan: a cross-sectional study. J Clin Med. 2025;14(4):1162.","journal-title":"J Clin Med"},{"issue":"2","key":"1666_CR6","first-page":"134","volume":"55","author":"T Tanaka","year":"2006","unstructured":"Tanaka T, Kameyoshi Y, Hide M. Analysis of the prevalence of subtypes of urticaria and angioedema. Arerugi. 2006;55(2):134\u20139.","journal-title":"Arerugi"},{"issue":"12","key":"1666_CR7","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/1346-8138.16562","volume":"49","author":"R Saito","year":"2022","unstructured":"Saito R, Takahagi S, Nakano F, et al. A survey on subtypes and clinical characteristics of 1061 patients with urticaria in the primary care institutes in Japan. J Dermatol. 2022;49(12):1255\u201362.","journal-title":"J Dermatol"},{"issue":"12","key":"1666_CR8","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1111\/all.13209","volume":"72","author":"M Maurer","year":"2017","unstructured":"Maurer M, Abuzakouk M, Berard F, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005\u201316.","journal-title":"Allergy"},{"issue":"10","key":"1666_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13102967","volume":"13","author":"A Fukunaga","year":"2024","unstructured":"Fukunaga A, Kishi Y, Arima K, Fujita H. Disease control and treatment satisfaction in patients with chronic spontaneous urticaria in Japan. J Clin Med. 2024;13(10):2967.","journal-title":"J Clin Med"},{"issue":"5","key":"1666_CR10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1365-2222.2007.02678.x","volume":"37","author":"RJ Powell","year":"2007","unstructured":"Powell RJ, Du Toit GL, Siddique N, et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy. 2007;37(5):631\u201350.","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"1666_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1046\/j.1365-2133.1997.d01-1168.x","volume":"136","author":"BF O'Donnell","year":"1997","unstructured":"O\u2019Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136(2):197\u2013201.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1666_CR12","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/bjd.19561","volume":"184","author":"M Goncalo","year":"2021","unstructured":"Goncalo M, Gimenez-Arnau A, Al-Ahmad M, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021;184(2):226\u201336.","journal-title":"Br J Dermatol"},{"issue":"11","key":"1666_CR13","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1111\/jdv.19940","volume":"38","author":"M Maurer","year":"2024","unstructured":"Maurer M, Augustin M, Bauer S, et al. Modelling of patient journey in chronic spontaneous urticaria: increasing awareness and education by shorten patients\u2019 disease journey in Germany. J Eur Acad Dermatol Venereol. 2024;38(11):2093\u2013101.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1666_CR14","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.jaci.2014.02.036","volume":"133","author":"JA Bernstein","year":"2014","unstructured":"Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1666_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","volume":"66","author":"M Maurer","year":"2011","unstructured":"Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticarial. A GA(2)LEN task force report. Allergy. 2011;66(3):317\u201330.","journal-title":"Allergy"},{"key":"1666_CR16","unstructured":"Regeneron. Dupixent (dupilumab) injection. Accessed at: \u30c7\u30e5\u30d4\u30af\u30bb\u30f3\u30c8\u76ae\u4e0b\u6ce8300mg\u30da\u30f3\u3001\u30c7\u30e5\u30d4\u30af\u30bb\u30f3\u30c8\u76ae\u4e0b\u6ce8300mg\u30b7\u30ea\u30f3\u30b8\u3001\u30c7\u30e5\u30d4\u30af\u30bb\u30f3\u30c8\u76ae\u4e0b\u6ce8200mg\u30b7\u30ea\u30f3\u30b8 [press release]. Accessed Apr 3, 2025."},{"issue":"2","key":"1666_CR17","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jaci.2015.08.023","volume":"137","author":"A Kaplan","year":"2016","unstructured":"Kaplan A, Ferrer M, Bernstein JA, et al. Timing and duration of omalizumab response in patients with chronic idiopathic\/spontaneous urticaria. J Allergy Clin Immunol. 2016;137(2):474\u201381.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"1666_CR18","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.alit.2022.09.003","volume":"72","author":"M Hide","year":"2023","unstructured":"Hide M, Fukunaga A, Suzuki T, et al. Real-world safety and effectiveness of omalizumab in Japanese patients with chronic spontaneous urticaria: a post-marketing surveillance study. Allergol Int. 2023;72(2):286\u201396.","journal-title":"Allergol Int"},{"key":"1666_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.668131","volume":"9","author":"SFH Neys","year":"2021","unstructured":"Neys SFH, Hendriks RW, Corneth OBJ. Targeting Bruton\u2019s tyrosine kinase in inflammatory and autoimmune pathologies. Front Cell Dev Biol. 2021;9:668131.","journal-title":"Front Cell Dev Biol"},{"issue":"10","key":"1666_CR20","doi-asserted-by":"publisher","first-page":"5102","DOI":"10.1021\/acs.jmedchem.9b01916","volume":"63","author":"D Angst","year":"2020","unstructured":"Angst D, Gessier F, Janser P, et al. Discovery of LOU064 (remibrutinib), a potent and highly selective covalent inhibitor of Bruton\u2019s tyrosine kinase. J Med Chem. 2020;63(10):5102\u201318.","journal-title":"J Med Chem"},{"issue":"5","key":"1666_CR21","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1111\/cts.13005","volume":"14","author":"M Kaul","year":"2021","unstructured":"Kaul M, End P, Cabanski M, et al. Remibrutinib (LOU064): a selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase\u00a0I trial. Clin Transl Sci. 2021;14(5):1756\u201368.","journal-title":"Clin Transl Sci"},{"issue":"6","key":"1666_CR22","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.jaci.2022.08.027","volume":"150","author":"M Maurer","year":"2022","unstructured":"Maurer M, Berger W, Gimenez-Arnau A, et al. Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria. J Allergy Clin Immunol. 2022;150(6):1498-506.e2.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1666_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12227","volume":"13","author":"R Gimeno","year":"2023","unstructured":"Gimeno R, Ribas-Llaurado C, Pesque D, et al. Remibrutinib inhibits hives effector cells stimulated by serum from chronic urticaria patients independently of FcepsilonR1 expression level and omalizumab clinical response. Clin Transl Allergy. 2023;13(3):e12227.","journal-title":"Clin Transl Allergy"},{"issue":"10","key":"1666_CR24","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1080\/1744666X.2017.1370374","volume":"13","author":"MC Dispenza","year":"2017","unstructured":"Dispenza MC, Regan JA, Bochner BS. Potential applications of Bruton\u2019s tyrosine kinase inhibitors for the prevention of allergic reactions. Expert Rev Clin Immunol. 2017;13(10):921\u20133.","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"1666_CR25","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaci.2023.10.007","volume":"153","author":"V Jain","year":"2024","unstructured":"Jain V, Gimenez-Arnau A, Hayama K, et al. Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52\u00a0weeks. J Allergy Clin Immunol. 2024;153(2):479\u201386.e4.","journal-title":"J Allergy Clin Immunol"},{"issue":"5, Suppl 2","key":"1666_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.10.019","volume":"131","author":"S Saini","year":"2023","unstructured":"Saini S, Gim\u00e9nez-Arnau A, Hide M, et al. Fast symptom improvement and favorable safety profile with remibrutinib in chronic spontaneous urticaria: REMIX-1\/-2 studies. Ann Allergy Asthma Immunol. 2023;131(5, Suppl 2):S230.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10","key":"1666_CR27","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1056\/NEJMoa2408792","volume":"392","author":"M Metz","year":"2025","unstructured":"Metz M, Gimenez-Arnau A, Hide M, et al. Remibrutinib in chronic spontaneous urticaria. N Engl J Med. 2025;392(10):984\u201394.","journal-title":"N Engl J Med"},{"issue":"1","key":"1666_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jaci.2025.09.028","volume":"157","author":"AM Gim\u00e9nez-Arnau","year":"2026","unstructured":"Gim\u00e9nez-Arnau AM, Szalewski R, Hide M, et al. Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase\u00a03 studies. J Allergy Clin Immunol. 2026;157(1):143-54.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1666_CR29","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.jaci.2011.01.045","volume":"127","author":"MJ Biagtan","year":"2011","unstructured":"Biagtan MJ, Viswanathan RK, Evans MD, Mathur SK. Clinical utility of the chronic urticaria index. J Allergy Clin Immunol. 2011;127(6):1626\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"20","key":"1666_CR30","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.1111\/bph.17344","volume":"182","author":"S Chen","year":"2025","unstructured":"Chen S, Liu Y, Zhang Y, et al. Bruton\u2019s tyrosine kinase inhibition suppresses pathological retinal angiogenesis. Br J Pharmacol. 2025;182(20):4944\u201367.","journal-title":"Br J Pharmacol"},{"key":"1666_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177747","volume":"1002","author":"R Pulz","year":"2025","unstructured":"Pulz R, Angst D, Cenni B. Next generation Bruton\u2019s tyrosine kinase inhibitors - characterization of in vitro potency and selectivity. Eur J Pharmacol. 2025;1002:177747.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1666_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.anai.2011.09.008","volume":"108","author":"SD Mathias","year":"2012","unstructured":"Mathias SD, Crosby RD, Zazzali JL, Maurer M, Saini SS. Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2012;108(1):20\u20134.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1666_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-3-36","volume":"3","author":"R Shikiar","year":"2005","unstructured":"Shikiar R, Harding G, Leahy M, Lennox RD. Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI): results from patients with chronic idiopathic urticaria. Health Qual Life Outcomes. 2005;3:36.","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"1666_CR34","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jaci.2023.03.034","volume":"152","author":"T Buttgereit","year":"2023","unstructured":"Buttgereit T, Salameh P, Sydorenko O, et al. The 7-day recall period version of the urticaria control test-UCT7. J Allergy Clin Immunol. 2023;152(5):1210-17.e14.","journal-title":"J Allergy Clin Immunol"},{"key":"1666_CR35","unstructured":"Guidelines https:\/\/www.ismpp.org\/gpp2022."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01666-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01666-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01666-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:06:17Z","timestamp":1774371977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01666-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1666"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01666-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Koremasa Hayama was the principal investigator for the BISCUIT trial and an advisor for Novartis, Sanofi, and Boehringer Ingelheim. He received honoraria for lectures from Kaken Pharmaceutical, Kyowa Kirin, Kyorin Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Novartis, Sanofi, Taiho Pharmaceutical, and Boehringer Ingelheim and grants for his facility from Kaken Pharmaceutical, Kyorin Pharmaceutical, Kyowa Kirin, Mitsubishi Tanabe Pharma, and Taiho Pharmaceutical. Yuko Chinuki received honoraria for lectures from Novartis, Mitsubishi Tanabe Pharma, Sanofi, Taiho Pharmaceutical, Kaken Pharmaceutical, and Meiji Seika Pharma. Akiko Yagami received honoraria for lectures from Novartis, AbbVie, Otsuka Pharmaceutical, Kaken Pharmaceutical, Sanofi, Taiho Pharmaceutical, Tanabe Pharma, Torii Pharmaceutical, Eli Lilly Japan KK, Pfizer, Maruho and LEO Pharma and received grants from Novartis, Sanofi, and Maruho. Akihiro Kume has no conflict of interest to disclose. Atsuya Morita and Sakiko Miyazu are employees of Novartis Pharma K.K., Tokyo, Japan. Karine Lheritier, Lukasz Jaskiewicz, and Sibylle Haemmerle are employees of Novartis Pharma AG, Basel, Switzerland. Michihiro Hide has received lecture and\/or consultation fees from Japan Tabacco, Kaken Pharmaceutical, Kyorin Pharmaceutical, Kyowa Kirin, Meiji Seiyaku, Mitsubishi Tanabe Pharma, Nippon Zoki, Novartis, Sanofi, Taiho Pharmaceutical, Teikoku Seiyaku and Yuhan. Michihiro Hide is an Editorial Board member of\n                      Dermatology and Therapy\n                      and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The sponsor (Novartis Pharma AG, Basel, Switzerland) and the program steering committee collaboratively designed the study and interpreted the data. The study was conducted in accordance with the principles of the Declaration of Helsinki, Good Clinical Practice guidelines, and applicable local regulations. Investigators\/institutions obtained approval from the institutional review board\/independent ethics committees for the study protocol before starting the study. All participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}